AAA
FULC icon

Affinity Asset Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Affinity Asset Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-250,000
Closed -$1.55M – 92
2024
Q2 		$1.55M Sell
250,000
-25,000
-9% -$189K 0.18% 70
2024
Q1 		$2.6M Buy
+275,000
New +$2.45M 0.32% 68

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Affinity Asset Advisors's FULC Position: Q2 2024 in Review

Affinity Asset Advisors sold out of Fulcrum Therapeutics (FULC) in Q2 2024, closing a stake of 550,339 shares — an estimated $4.17M sold.

Affinity Asset Advisors first reported a position in FULC in Q4 2023 and held it in 2 quarters. The position peaked at $5.2M in Q1 2024. 121 funds tracked by Wall St. Rank hold FULC as of Q2 2024.

  • Affinity Asset Advisors reported no remaining Fulcrum Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 550,339 Fulcrum Therapeutics shares in Q2 2024, an estimated $4.17M.
  • Affinity Asset Advisors first reported a position in Fulcrum Therapeutics in Q4 2023 and held it in 2 quarters.
  • Affinity Asset Advisors's Fulcrum Therapeutics position peaked at $5.2M in Q1 2024.
  • 121 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2024.

Based on Affinity Asset Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.